林业发展局接受对Replimune用于Nivolumab的黑瘤治疗RP1的优先审查。 FDA accepts priority review for Replimune's melanoma treatment RP1, used with Nivolumab.

美国食品和药物管理局已接受Replimune Group与Nivolumab一起使用的黑色素瘤治疗RP1的申请进行优先审查,预计将于2025年7月作出决定. Replimune Group's application for its melanoma treatment RP1, used with Nivolumab, has been accepted by the FDA for priority review, with a decision expected by July 2025. 这是在IGNYTE试验的积极结果之后,并使Replimune的库存增加了25%以上. This follows positive results from the IGNYTE trial and has boosted Replimune's stock by over 25%. 这种治疗旨在加强人体对肿瘤的免疫反应。 The treatment aims to enhance the body's immune response against tumors.